Repurposing metformin for cancer treatment: current clinical studies.
Repurposing metformin for cancer treatment: current clinical studies.
复制标题
DOI：
10.18632/oncotarget.8194
复制
发表时间：
2016-06-28
期刊：
影响因子：
--
通讯作者：
Giles F
中科院分区：
文献类型：
--
作者：
Chae YK;Arya A;Malecek MK;Shin DS;Carneiro B;Chandra S;Kaplan J;Kalyan A;Altman JK;Platanias L;Giles F
近年来，一些研究已经提出证据表明二甲双胍在抗癌治疗中的潜在作用。临床前研究已经证明了二甲双胍的几种抗癌分子机制，包括mTOR抑制、细胞毒性作用和免疫调节。流行病学数据表明，服用二甲双胍的患者癌症发病率和死亡率降低。目前正在进行几项临床试验，重点是评估二甲双胍作为抗癌药物的作用。从少数已完成的试验中公布的数据已经提出了有趣的结果。在术前子宫内膜癌患者中进行的临床试验显示，二甲双胍单药治疗可显著降低Ki67。在乳腺癌患者中进行了另一个有趣的观察，其中在没有胰岛素抵抗的患者中注意到癌症增殖标志物改善的趋势。使用二甲双胍作为抗癌药物的生存结局数据正在等待中。本文将对二甲双胍作为一种潜在的癌症治疗方法的作用进行批判性综述。
In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment.
登录
查看更多内容
DOI：
10.1056/nejmoa1504030
发表时间：
2015-07-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者：
Wolchok JD
影响因子：
4.8
作者：
Joshua, A. M.;Zannella, V. E.;Pollak, M.
通讯作者：
Pollak, M.
影响因子：
2.4
作者：
Kalinsky K;Crew KD;Refice S;Xiao T;Wang A;Feldman SM;Taback B;Ahmad A;Cremers S;Hibshoosh H;Maurer M;Hershman DL
通讯作者：
Hershman DL
影响因子：
--
作者：
Del Barco S;Vazquez-Martin A;Cufí S;Oliveras-Ferraros C;Bosch-Barrera J;Joven J;Martin-Castillo B;Menendez JA
通讯作者：
Menendez JA
影响因子：
3.8
作者：
Hadad, Sirwan M.;Coates, Philip;Thompson, Alastair M.
通讯作者：
Thompson, Alastair M.